Automated LC-MS/MS testing platforms successfully validated cannabinoid detection alongside other substances in public health overdose surveillance programs. This technology enables real-time monitoring of polysubstance use patterns involving cannabis, though clinical interpretation requires distinguishing coincidental use from causal contribution. The validation represents a technical advance in drug surveillance capabilities without establishing clinical outcomes or cannabis-overdose causation.